Search research articles
Contact Us
Filters
Showing results (111-120 of 169) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 27, 2018
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study
Uday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, et al.
Targeted Oncology
|
September 30, 2018
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
Alice Tzeng, C Marcela Diaz-Montero, Patricia A Rayman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2020
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Shipra Gandhi, Manu R Pandey, Kristopher Attwood, et al.
Cancer
|
December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
Walter M Stadler, David J Vaughn, Guru Sonpavde, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 15, 2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure
Nizar M Tannir, Yu-Ning Wong, Christian K Kollmannsberger, et al.
International Journal of Molecular Sciences
|
October 26, 2024
Immune Checkpoint Inhibitor Therapy and Associations with Clonal Hematopoiesis
Abhay Singh, Nuria Mencia Trinchant, Rahul Mishra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2019
Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma
Robyn D Gartrell, Douglas K Marks, Emanuelle M Rizk, et al.
Neuro-Oncology
|
January 26, 2015
Regulatory T cells are not a strong predictor of survival for patients with glioblastoma
Alissa A Thomas, Jan L Fisher, Gilbert J Rahme, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 169) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 27, 2018
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study
Uday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, et al.
Targeted Oncology
|
September 30, 2018
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
Alice Tzeng, C Marcela Diaz-Montero, Patricia A Rayman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2020
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Shipra Gandhi, Manu R Pandey, Kristopher Attwood, et al.
Cancer
|
December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
Walter M Stadler, David J Vaughn, Guru Sonpavde, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 15, 2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure
Nizar M Tannir, Yu-Ning Wong, Christian K Kollmannsberger, et al.
International Journal of Molecular Sciences
|
October 26, 2024
Immune Checkpoint Inhibitor Therapy and Associations with Clonal Hematopoiesis
Abhay Singh, Nuria Mencia Trinchant, Rahul Mishra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2019
Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma
Robyn D Gartrell, Douglas K Marks, Emanuelle M Rizk, et al.
Neuro-Oncology
|
January 26, 2015
Regulatory T cells are not a strong predictor of survival for patients with glioblastoma
Alissa A Thomas, Jan L Fisher, Gilbert J Rahme, et al.
Page
of 17